Physician profile
Matthew Ryan Brown
NPI 1912223447
$9,350.37
in general payments reported to CMS, 2019-2025
11 companies · $33.38 in 2025
The $33.38 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,810 · 2020: $1,073 · 2021: $109 · 2022: $87.37 · 2024: $238 · 2025: $33.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,821.06 | 2019-2024 | |
| Davol INC. | $130.16 | 2019-2024 | Arista Ah Flexitip, Tridyne Vascular Sealant |
| Smith+Nephew, INC. | $91.07 | 2021-2024 | Stravix |
| Integra Lifesciences Corporation | $73.46 | 2024 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Abbvie INC. | $67.54 | 2021-2022 | |
| Allergan, INC. | $52.75 | 2019 | |
| Innocoll Pharmaceuticals Limited | $39.22 | 2021-2022 | |
| Livanova USA, INC. | $27.26 | 2020 | |
| Microline Surgical INC | $16.82 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $16.56 | 2025 | Exparel |
| Conmed Corporation | $14.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.